Oligomeric aggregates of amyloid β peptide 1-42 activate ERK/MAPK in SH-SY5Y cells via the α7 nicotinic receptor

Neurochemistry International

Volumn 55, Issue 8, 2009, Pages 796-801

  Young, Kirk F ^a,b   Pasternak, Stephen H ^a,b   Rylett, R Jane ^a,b  

^a WESTERN UNIVERSITY   (Canada)

^b ROBARTS RESEARCH INSTITUTE   (Canada)

Author keywords

7 nicotinic receptor; Amyloid beta; Atomic force microscopy; ERK MAPK; Fibrillar amyloid; Oligomeric amyloid; SH SY5Y cells

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; AMYLOID BETA PROTEIN[1-42]; BUNGAROTOXIN RECEPTOR; METHYLLYCACONITINE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; NEUROBLASTOMA CELL; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; ENZYME INHIBITORS; HUMANS; MAP KINASE KINASE 1; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE 3; NEUROFIBRILLARY TANGLES; NEURONS; NICOTINIC ANTAGONISTS; PEPTIDE FRAGMENTS; PHOSPHORYLATION; POLYMERS; RECEPTORS, NICOTINIC; TIME FACTORS;

EID: 70349952431     PISSN: 01970186     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuint.2009.08.002     Document Type: Article

References (49)

1. Bell K.A., O'Riordan K.J., Sweatt J.D., and Dineley K.T. MAPK recruitment by β-amyloid in organotypic hippocampal slice cultures depends on physical state and exposure time. J. Neurochem. 91 (2004) 349-361
2. Bitner R.S., Bunnelle W.H., Anderson D.J., Briggs C.A., Buccafusco J., Curzon P., Decker M.W., Frost J.M., Gronlien J.H., Gubbins E., Li J., Malysz J., Markosyan S., Marsh K., Meyer M.D., Nikkel A.L., Radek R.J., Robb H.M., Timmermann D., Sullivan J.P., and Gopalakrishnan M. Broad-spectrum efficacy across cognitive domains by α7 nicotinic acetylcholine receptor agonism correlates with activation of ERK1/2 and CREB phosphorylation pathways. J. Neurosci. 27 (2007) 10578-10587
3. Bouwman F.H., Schoonenboom N.S., Verwey N.A., van Elk E.J., Kok A., Blankenstein M.A., Scheltens P., and van der Flier W.M. CSF biomarker levels in early and late onset Alzheimer's disease. Neurobiol. Aging (2008) (Epub ahead of print)
4. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72 (1976) 248-254
5. Burdick D., Soreghan B., Kwon M., Kosmoski J., Knauer M., Henschen A., Yates J., Cotman C., and Glabe C. Assembly and aggregation properties of synthetic Alzheimer's A4/β amyloid peptide analogs. J. Biol. Chem. 267 (1992) 546-554
6. Dahlgren K.N., Manelli A.M., Stine Jr. W.B., Baker L.K., Krafft G.A., and LaDuF M.J. Oligomeric and fibrillar species of amyloid-β peptides differentially affect neuronal viability. J. Biol. Chem. 277 (2002) 32046-32053
7. 2+ stores. J. Neurochem. 81 (2002) 606-614
8. Dajas-Bailador F.A., Soliakov L., and Wonnacott S. Nicotine activates the extracellular signal-regulated kinase 1/2 via the α7 nicotinic acetylcholine receptor and protein kinase A, in SH-SY5Y cells and hippocampal neurones. J. Neurochem. 80 (2002) 520-530
9. 3H]methyllycaconitine: a new radioligand for labelling α7-type neuronal nicotinic acetylcholine receptors. Neuropharmacology 38 (1999) 679-690
10. DeSilva D.R., Jones E.A., Favata M.F., Jaffee B.D., Magolda R.L., Trzaskos J.M., and Scherle P.A. Inhibition of mitogen-activated protein kinase kinase blocks T cell proliferation but does not induce or prevent anergy. J. Immunol. 160 (1998) 4175-4181
11. Dickson D.W., Crystal H.A., Bevona C., Honer W., Vincent I., and Davies P. Correlations of synaptic and pathological markers with cognition of the elderly. Neurobiol. Aging 16 (1995) 285-298 discussion 298-304
12. Dineley K.T., Bell K.A., Bui D., and Sweatt J.D. β-Amyloid peptide activates α7 nicotinic acetylcholine receptors expressed in Xenopus oocytes. J. Biol. Chem. 277 (2002) 25056-25061
13. Dineley K.T., Westerman M., Bui D., Bell K., Ashe K.H., and Sweatt J.D. β-amyloid activates the mitogen-activated protein kinase cascade via hippocampal α7 nicotinic acetylcholine receptors: in vitro and in vivo mechanisms related to Alzheimer's disease. J. Neurosci. 21 (2001) 4125-4133
14. Garzon D.J., and Fahnestock M. Oligomeric amyloid decreases basal levels of brain-derived neurotrophic factor (BDNF) mRNA via specific downregulation of BDNF transcripts IV and V in differentiated human neuroblastoma cells. J. Neurosci. 27 (2007) 2628-2635
15. Georganopoulou D.G., Chang L., Nam J.M., Thaxton C.S., Mufson E.J., Klein W.L., and Mirkin C.A. Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 2273-2276
16. Gopalakrishnan M., Buisson B., Touma E., Giordano T., Campbell J.E., Hu I.C., Donnelly-Roberts D., Arneric S.P., Bertrand D., and Sullivan J.P. Stable expression and pharmacological properties of the human α7 nicotinic acetylcholine receptor. Eur. J. Pharmacol. 290 (1995) 237-246
17. Grassi F., Palma E., Tonini R., Amici M., Ballivet M., and Eusebi F. Amyloid β(1-42) peptide alters the gating of human and mouse α-bungarotoxin-sensitive nicotinic receptors. J. Physiol. 547 (2003) 147-157
18. Haass C. Take five-BACE and the gamma-secretase quartet conduct Alzheimer's amyloid β-peptide generation. EMBO J. 23 (2004) 483-488
19. Hepler R.W., Grimm K.M., Nahas D.D., Breese R., Dodson E.C., Acton P., Keller P.M., Yeager M., Wang H., Shughrue P., Kinney G., and Joyce J.G. Solution state characterization of amyloid β-derived diffusible ligands. Biochemistry 45 (2006) 15157-15167
20. Iwatsubo T., Odaka A., Suzuki N., Mizusawa H., Nukina N., and Ihara Y. Visualization of Aβ 42(43) and Aβ 40 in senile plaques with end-specific Aβ monoclonals: evidence that an initially deposited species is Aβ 42(43). Neuron 13 (1994) 45-53
21. Jarrett J.T., Berger E.P., and Landsbury J.T. The carboxy terminus of the β amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry 32 (1993) 4693-4697
22. Joerchel S., Raap M., Bigl M., Eschrich K., and Schliebs R. Oligomeric β-amyloid(1-42) induces the expression of Alzheimer disease-relevant proteins in cholinergic SN56.B5. G4 cells as revealed by proteomic analysis. Int. J. Dev. Neurosci. (2008) 301-308
23. Kim H., Kim J., Chae S., Park Y., Kwon K., and Hong S. Soluble oligomeric Aβ disrupts the protein kinase C signaling pathway. Neuroreport 15 (2004) 503-507
24. Kirkitadze M.D., Bitan G., and Teplow D.B. Paradigm shifts in Alzheimer's disease and other neurodegenerative disorders: the emerging role of oligomeric assemblies. J. Neurosci. Res. 69 (2002) 567-577
25. Koffie R.M., Meyer-Luehmann M., Hashimoto T., Adams K.W., Mielke M.L., Garcia-Alloza M., Micheva K.D., Smith S.J., Kim M.L., Lee V.M., Hyman B.T., and Spires-Jones T.L. Oligomeric amyloid β associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Proc. Natl. Acad. Sci. 106 (2009) 4012-4017
26. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227 (1970) 680-685
27. Lambert M.P., Barlow A.K., Chromy B.A., Edwards C., Freed R., Liosatos M., Morgan T.E., Rozovsky I., Trommer B., Viola K.L., Wals P., Zhang C., Finch C.E., Krafft G.A., and Klein W.L. Diffusible, nonfibrillar ligands derived from Aβ1-42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 6448-6453
28. Lee D.H., and Wang H.Y. Differential physiologic responses of α7 nicotinic acetylcholine receptors to β-amyloid1-40 and β-amyloid1-42. J. Neurobiol. 55 (2003) 25-30
29. Lisman J. Long-term potentiation: outstanding questions and attempted synthesis. Philos. Trans. Roy. Soc., Lond. B: Biol. Sci. 358 (2003) 829-842
30. Lue L.F., Kuo Y.M., Roher A.E., Brachova L., Shen Y., Sue L., Beach T., Kurth J.H., Rydel R.E., and Rogers J. Soluble amyloid β peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am. J. Pathol. 155 (1999) 853-862
31. Ma Q.L., Harris-White M.E., Ubeda O.J., Simmons M., Beech W., Lim G.P., Teter B., Frautschy S.A., and Cole G.M. Evidence of Abeta- and transgene-dependent defects in ERK-CREB signalling in Alzheimer's models. J. Neurochem. 103 (2007) 1594-1607
32. McLean C.A., Cherny R.A., Fraser F.W., Fuller S.J., Smith M.J., Beyreuther K., Bush A.I., and Masters C.L. Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann. Neurol. 46 (1999) 860-866
33. Morishima-Kawashima M., and Ihara Y. The presence of amyloid β-protein in the detergent-insoluble membrane compartment of human neuroblastoma cells. Biochemistry 37 (1998) 15247-15253
34. Podlisny M.B., Ostaszewski B.L., Squazzo S.L., Koo E.H., Rydell R.E., Teplow D.B., and Selkoe D.J. Aggregation of secreted amyloid β-protein into sodium dodecyl sulfate-stable oligomers in cell culture. J. Biol. Chem. 270 (1995) 9564-9570
35. Reese L.C., Zhang W.R., Dineley K.T., Kayed R., and Taglialatela G. Selective induction of calcineurin activity and signaling by oligomeric amyloid beta. Aging Cell 7 (2008) 824-835
36. Ridley D.L., Rogers A., and Wonnacott S. Differential effects of chronic drug treatment on α3* and α7 nicotinic receptor binding sites, in hippocampal neurones and SH-SY5Y cells. Br. J. Pharmacol. 133 (2001) 1286-1295
37. Selkoe D.J., and Podlisny M.B. Deciphering the genetic basis of Alzheimer's disease. Annu. Rev. Genomics Hum. Genet. 3 (2002) 67-99
38. Sluimer J.D., Bouwman F.H., Vrenken H., Blankenstein M.A., Barkhof F., van der Flier W.M., and Scheltens P. Whole-brain atrophy rate and CSF biomarker levels in MCI and AD: a longitudinal study. Neurobiol. Aging (2008) (Epub ahead of print)
39. Smach M.A., Charfeddine B., Lammouchi T., Harrabi I., Ben Othman L., Dridi H., Bennamou S., and Limem K. CSF β-amyloid 1-42 and tau in Tunisian patients with Alzheimer's disease: the effect of APOE epsilon4 allele. Neurosci. Lett. 440 (2008) 145-149
40. Small D.H., Maksel D., Kerr M., Ng J., Hou X., Chu C., Mehrani H., Unabia S., Azari M.F., Loiacono R., Aguilar M.I., and Chebbib M. The β-amyloid protein of Alzheimer's disease binds to membrane lipids but does not bind to the α7 nicotinic acetylcholine receptor. J. Neurochem. 101 (2007) 1527-1538
41. Smolen P., Baxter D.A., and Byrne J.H. A model of the roles of essential kinases in the induction and expression of late long-term potentiation. Biophys. J. 90 (2006) 2760-2775
42. Stine Jr. W.B., Dahlgren K.N., Krafft G.A., and LaDu M.J. In vitro characterization of conditions for amyloid-β peptide oligomerization and fibrillogenesis. J. Biol. Chem. 278 (2003) 11612-11622
43. Sweatt J.D. The neuronal MAP kinase cascade: a biochemical signal integration system subserving synaptic plasticity and memory. J. Neurochem. 76 (2001) 1-10
44. Terry R.D., Masliah E., Salmon D.P., Butters N., DeTeresa R., Hill R., Hansen L.A., and Katzman R. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann. Neurol. 30 (1991) 572-580
45. Townsend M., Mehta T., and Selkoe D.J. Soluble Aβ inhibits specific signal transduction cascades common to the insulin receptor pathway. J. Biol. Chem. 282 (2007) 33305-33312
46. Walsh D.M., Klyubin I., Fadeeva J.V., Cullen W.K., Anwyl R., Wolfe M.S., Rowan M.J., and Selkoe D.J. Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416 (2002) 535-539
47. Walsh D.M., and Selkoe D.J. Aβ oligomers-a decade of discovery. J. Neurochem. 101 (2007) 1172-1184
48. Walsh D.M., Tseng B.P., Rydel R.E., Podlisny M.B., and Selkoe D.J. The oligomerization of amyloid β-protein begins intracellularly in cells derived from human brain. Biochemistry 39 (2000) 10831-10839
49. Wang H.Y., Li W., Benedetti N.J., and Lee D.H. α7 nicotinic acetylcholine receptors mediate β-amyloid peptide-induced tau protein phosphorylation. J. Biol. Chem. 278 (2003) 31547-31553